NR1H4 and Hepatic fibrosis: Using this methodology, the current study undertook an in‐depth, quantitative evaluation of changes in liver fibrosis overall and individual septa parameters in a homogenous, well‐characterised group of patients with bridging MASH fibrosis (F3 stage), who participated in the FLIGHT‐farnesoid X receptor (FXR) clinical trial (NCT02855164).